Tarsus Pharmaceuticals, Inc.
TARS
Ранг среди акций
#4544
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Цена акции
$70.30
Рыночная капитализация
$3.29B
Изменение (1 день)
-0.29%
Изменение (1 год)
2.32%
Страна
US
Торговля Tarsus Pharmaceuticals, Inc. (TARS)
Категория
Healthcare
История цены акций Tarsus Pharmaceuticals, Inc. (TARS)
Наивысшая цена закрытия: $72.19 2026-10-01
Наименьшая цена закрытия: $21.51 2020-10-01
Наименьшая цена закрытия: $21.51 2020-10-01
История цены акций Tarsus Pharmaceuticals, Inc. с 2020 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $536.91 | 25.90% |
US
|
|
| $230.20 | 757.36% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $892.44 | 9.61% |
NL
|
